Cost-effectiveness of treatment of diabetic macular edema

Annals of Internal Medicine

Volumn 160, Issue 1, 2014, Pages 18-29

  Pershing, Suzann ^a   Enns, Eva A ^b   Matesic, Brian ^a   Owens, Douglas K ^c   Goldhaber Fiebert, Jeremy D ^c  

^a 12452 Watson Court ^*  (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; TRIAMCINOLONE; AFLIBERCEPT; ANTIBIOTIC AGENT; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; CATARACT; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DISEASE COURSE; DRUG COST; ENDOPHTHALMITIS; FEMALE; GLAUCOMA; HEALTH CARE COST; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; DRUG EFFICACY; TRABECULECTOMY;

ADMINISTRATION, OPHTHALMIC; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; LASER THERAPY; MACULAR EDEMA; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84892505273     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/m13-0768     Document Type: Article

References (77)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Accessed at www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf on 8 December 2011.
2. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004;18:963-83. [PMID: 15232600]
3. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009; 116:497-503. [PMID: 19167079]
4. Klein R, Klein BE, Moss SE. The epidemiology of ocular problems in diabetes mellitus. In: Ferman SS, ed. Ocular Problems in Diabetes Mellitus. Boston: Blackwell Scientific; 1991: 1-51.
5. Gangnon RE, Davis MD, Hubbard LD, Aiello LM, Chew EY, Ferris FL 3rd, et al; Early Treatment Diabetic Retinopathy Study Research Group. A severity scale for diabetic macular edema developed from ETDRS data. Invest Ophthalmol Vis Sci. 2008;49:5041-7. [PMID: 18539929]
6. Shea AM, Curtis LH, Hammill BG, Kowalski JW, Ravelo A, Lee PP, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol. 2008;126:1748-54. [PMID: 19064859]
7. Centers for Medicare & Medicaid Services. Medicare ASP Drug Pricing Files, October 2010 Update. Accessed at www.cms.gov/McrPartBDrugAvgSalesPrice/ on 18 September 2012.
8. Centers for Medicare & Medicaid Services. Medicare Outpatient Addendum A and B Updates. Accessed at www.cms.gov/HospitalOutpatientPPS/AU/list. asp #TopOfPage on 8 December 2011.
9. Physicians' Desk Reference. Red Book: Pharmacy's Fundamental Reference. 2010 Edition. Montvale, NJ: Thomson-Reuters PDR Network; 2010.
10. Levinson DR. Department of Health and Human Services Review of Medicare Part B Avastin and Lucentis Treatments for Age-Related Macular Degeneration (A-01-10-00514). 6 September 2011. on 5 November 2013. Accessed at http://oig.hhs.gov/oas/reports/region10/11000514.pdf on 5 November 2013.
11. Alcon. Triesence Suspension (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL Coding and Reimbursement Fact Sheet. Accessed at https: //www.myalcon.com/docs/ars-TRIESENCE-fact-sheet-single.pdf on 5 November 2013.
12. National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence Final Appraisal Determination: Ranibizumab for the Treatment of Macular Oedema. July 2011. Accessed at www.nice.org.uk /nicemedia/live/13125/55324/55324.pdf on 30 June 2012.
13. Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96:688-93. [PMID: 22399690]
14. Dewan V, Lambert D, Edler J, Kymes S, Apte RS. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2012;119:1679-84. [PMID: 22503301]
15. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954-61. [PMID: 11035892]
16. Ruiz MS; Committee on HIV Prevention Strategies in the United States. No Time to Lose: Getting More from HIV Prevention. Washington, DC: National Academies Pr; 2001.
17. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346:1800-6. [PMID: 12050341]
18. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-85. [PMID: 15703422]
19. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al; Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353:2158-68. [PMID: 16291985]
20. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-80. [PMID: 16207849]
21. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-25. [PMID: 21459215]
22. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077. [PMID: 20427088]
23. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, et al; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609-14. [PMID: 21459214]
24. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, et al; Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119:2312-8. [PMID: 22999634]
25. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-9. [PMID: 18662829]
26. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al; Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009; 127:245-51. [PMID: 19273785]
27. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51. [PMID: 20855114]
28. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al; READ-2 Study Group. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009;116: 2175-81. [PMID: 19700194]
29. Bandello F, Lang GE, Schlingemann RO, Leclair D, Weichselberger A. Pooled safety analysis in patients with visual impairment due to diabetic macular edema treated with 0.5 mg ranibizumab in RESOLVE and RESTORE trials [Abstract]. Presented at 47th European Association for the Study of Diabetes Annual Meeting in Lisbon, Portugal, 12-16 September 2011. Abstract 1122. Accessed at www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey-3af4f519 -dbbd-4b2d-8fe2-9e5360e8b8fd&cKey-e4bdbd0c-750d-40b7-9753-b1c0ea0 bef7f&mKey-%7bBAFB2746-B0DD-4110-8588-E385FAF957B7%7d on 5 November 2013.
30. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801. [PMID: 22330964]
31. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-405. [PMID: 20980427]
32. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796-806. [PMID: 2866759]
33. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:265-72. [PMID: 3692708]
34. Enns EA, Pershing S, Wang Y, Goldhaber-Fiebert JD. Calibration methods for inferring transition probabilities from cross-sectional studies [Abstract]. Presented at 34th Annual Meeting of the Society for Medical Decision Making, Phoenix, Arizona, 17-20 October 2012. Abstract I-4. Accessed at https://smdm .confex.com/smdm/2012az/webprogram/Paper7077.html on 5 November 2013.
35. Lövestam-Adrian M, Hansson-Lundblad C, Torffvit O. Sight-threatening retinopathy is associated with lower mortality in type 2 diabetic subjects: a 10- year observation study. Diabetes Res Clin Pract. 2007;77:141-7. [PMID: 17178168]
36. Xu L, Wang YX, Xie XW, Jonas JB. Retinopathy and mortality. The Beijing Eye Study. Graefes Arch Clin Exp Ophthalmol. 2008;246:923-5. [PMID: 18299875]
37. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol. 2006;124: 243-9. [PMID: 16476894]
38. Genentech. Lucentis [package insert]. San Francisco: Genentech; 2013. Accessed at www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf on 5 November 2013.
39. Genentech. Lucentis (Ranizumab Injection). San Francisco: Genentech; 2012.
40. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266-72. [PMID: 21664593]
41. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11. [PMID: 21041570]
42. Clark A, Ng JQ, Morlet N, Tropiano E, Mahendran P, Spilsbury K, et al. Quality of life after postoperative endophthalmitis. Clin Experiment Ophthalmol. 2008;36:526-31. [PMID: 18954314]
43. Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85:327-31. [PMID: 11222340]
44. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-50. [PMID: 17398322]
45. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al; da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658-65. [PMID: 22537617]
46. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078-1086. [PMID: 20416952]
47. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116:1142-50. [PMID: 19376585]
48. Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, et al; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125:469-80. [PMID: 17420366]
49. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al; Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860-7. [PMID: 17698196]
50. Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, et al. Intravitreal bevacizumab versus combined bevacizumabtriamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18:941-8. [PMID: 18988166]
51. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483-9. [PMID: 17917738]
52. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina. 2010;30:1638-45. [PMID: 20838357]
53. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249:15-27. [PMID: 20665044]
54. Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009-27. [PMID: 21394052]
55. Ockrim ZK, Sivaprasad S, Falk S, Roghani S, Bunce C, Gregor Z, et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol. 2008;92:795-9. [PMID: 18420749]
56. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a doublemasked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006; 113:1533-8. [PMID: 16828501]
57. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009;116:902-11. [PMID: 19410949]
58. Browning, DJ. Diabetic macular edema. In: Diabetic Retinopathy: Evidence-Based Management. New York: Springer; 2010:158.
59. Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2010;58:1-7. [PMID: 21043319]
60. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996; 276:1253-8. [PMID: 8849754]
61. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The costeffectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol. 2000;11:175-9. [PMID: 10977223]
62. Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128:324-30. [PMID: 10511027]
63. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabet Med. 2008;25:618-24. [PMID: 18346157]
64. Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol. 2001;12:230-4. [PMID: 11389353]
65. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc. 2008;6: 12. [PMID: 18573218]
66. Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental costeffectiveness ratios to ensure societal value. Can J Ophthalmol. 2005;40:369-77. [PMID: 15947806]
67. Sharma S, Brown GC, Brown MM, Shah GK, Snow K, Brown H, et al. Converting visual acuity to utilities. Can J Ophthalmol. 2000;35:267-72. [PMID: 10959467]
68. U.S. Census Bureau. Table 725: Consumer Price Indexes (CPIO) by Major Groups: 1990 to 2010. U.S. Census Bureau, Statistical Abstract of the United States: 2012. Accessed at www.census.gov/compendia/statab/2012/tables /12s0725.pdf on 8 December 2011.
69. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. Ophthalmology. 2007;114:238-45. [PMID: 17270673]
70. Schmier JK, Halpern MT, Covert D, Delgado J, Sharma S. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration. Retina. 2006;26:1056-62. [PMID: 17151494]
71. U.S. Bureau of Labor Statistics. Employment and Earnings. 2009. Table B-11. Accessed at www.bls.gov/opub/ee/empearn200912.pdf on 5 November 2013.
72. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
73. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med. 2011;364:1897-908. [PMID: 21526923]
74. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119: 1388-98. [PMID: 22555112]
75. van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011;31:1449-69. [PMID: 21817960]
76. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for agerelated macular degeneration. Arch Ophthalmol. 2010;128:1273-9. [PMID: 20937996]
77. Pollack A. Avastin injections are reported to cause blindness. New York Times. 30 August 2011. Accessed at www.nytimes.com/2011/08/31/health /31drug.html on 8 December 2011.